# Nxera Pharma Co (Nxera Pharma Co., Ltd.)

Other company type registered in Minato-Ku, classed under “None Supplied”.

- Company number: FC024112
- Status: Active
- Type: Other company type
- Incorporated: 1 April 2002
- Registered office: Midtown East 7f, 9-7-2 Akasaka, Minato-Ku, TOKYO 107-0052
- Location: Minato-Ku, Tokyo 107-0052
- Activity: None Supplied

## Latest filed profit

No profit figure in its latest filed accounts.

Turnover, net assets, cash, staff, earlier years, ratios and owners are on the page for subscribers.

## Questions people ask

### What does Nxera Pharma Co do?

Other company type registered in Minato-Ku, classed under “None Supplied”.

### How much turnover does Nxera Pharma Co make?

Answered on the page for FirmFacts Pro subscribers: https://firmfacts.co/company/nxera-pharma-co-fc024112

### Is Nxera Pharma Co profitable?

Nxera Pharma Co's profit isn't public: small companies may file without a profit and loss account.

### Who runs and owns Nxera Pharma Co?

Its directors are Christopher Cargill, David Doctor Roblin, Rolf-Kristian Soderstrom, Eiko Tomita. Its owners are shown to subscribers.

### Where is Nxera Pharma Co based?

Its registered office is Midtown East 7f, 9-7-2 Akasaka, Minato-Ku, TOKYO 107-0052, in Minato-Ku, Tokyo 107-0052.

### When was Nxera Pharma Co founded?

Nxera Pharma Co., Ltd. was incorporated on 1 April 2002.

### Is Nxera Pharma Co still trading?

The register lists Nxera Pharma Co., Ltd. as active.

## Timeline

Recent filings and changes at Companies House.

- 2026-08-20: Termination of appointment of Shinichi Tamura as a director on 26 March 2025
- 2026-08-20: Termination of appointment of Miwa Seki as a director on 25 March 2026
- 2026-08-20: Termination of appointment of Noriaki Nagai as a director on 25 March 2026
- 2026-08-20: Termination of appointment of Kuniaki Kaga as a director on 26 March 2025
- 2026-08-20: Termination of appointment of Tomohiro Tohyama as a director on 26 March 2025
- 2024-04-19: Group of companies' accounts made up to 31 December 2023
- 2024-04-17: Change of registered name of an overseas company on 4 April 2024 from Sosei group corporation
- 2024-04-17: Details changed for a UK establishment - BR006736 Name Change (and 3 more like it since 17 January 2012)
- 2024-04-17: Details changed for an overseas company (and 2 more like it since 26 March 2010)
- 2024-03-01: Group of companies' accounts made up to 31 December 2021
- 2024-02-09: Group of companies' accounts made up to 31 December 2022
- 2024-02-09: Details changed for an overseas company (and 13 more like it since 22 July 2015)
- 2023-11-03: Appointment of Miwa Seki as a director on 24 March 2022
- 2023-11-03: Appointment of Eiko Tomita as a director on 1 April 2023
- 2022-05-03: Appointment of Christopher Cargill as a director on 24 March 2022
- 2022-01-12: Appointment of Christopher Cargill as a person authorised to represent UK establishment BR006736 on 17 August 2021
- 2021-09-08: Group of companies' accounts made up to 31 December 2020
- 2021-04-13: Group of companies' accounts made up to 31 December 2019
- 2020-11-12: Appointment of Mr Rolf-Kristian Soderstrom as a director on 25 March 2020
- 2020-10-08: Termination of appointment of Julia Paige Gregory as a director on 25 March 2020
- 2019-11-26: Full accounts made up to 31 March 2018
- 2019-11-12: Full accounts made up to 31 March 2017
- 2019-11-08: Full accounts made up to 31 December 2018
- 2019-11-08: Appointment of Julia Gregory as a director on 22 June 2017
- 2019-09-17: Appointment of Doctor David Roblin as a director on 22 June 2018

---

Source: Companies House filings (Open Government Licence v3.0). Figures are as filed; nothing is estimated. Page: https://firmfacts.co/company/nxera-pharma-co-fc024112